924 shares of Becton, Dickinson and Company (BDX) were recently bought by Wedmont Private Capital. Whether the company's balance sheet is tough enough to withstand any impending financial storms has been questioned. BDX has received an average broker rating of Moderate Buy. The company is planning to acquire Edwards Lifesciences' Critical Care Product Group for a cash deal of 4.2 billion dollars. Various shifts in company stock positions have been reported by firms including Gulf International Bank, Marcum Wealth LLC, and Rise Advisors. Significant growth in short interest has been recorded by BDX. News of BDX beating Q2 earnings estimates and raising its fiscal 2024 guidance has been highlighted. BDX's conservative accounting has been thought to lead to soft earnings. BDX has been named among Fortune's most innovative companies, with a deal inked to expand its Smart Connected Care Suite. Recent reports indicate that the company is outperforming competitors on strong trading days but also underperforming on certain days. The company's stock looks to have a pretty healthy balance sheet and is expected to meet its 2025 commitments, according to an analyst.
Becton Dickinson and BDX News Analytics from Thu, 09 Nov 2023 08:00:00 GMT to Sun, 23 Jun 2024 12:31:20 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
